On June 2, 2011, "Daily Economic News" disclosed that four of Bayer's birth control pills were under investigation in the EU and the United States because studies claimed that the products involved may have a higher risk of thrombosis than other products. product.
Four birth control pills produced by Bayer in Germany are under investigation by the FDA (U.S. Food and Drug Administration) because studies have shown that "consumers using these four birth control pills by Bayer may have a higher risk of blood clots than Other similar drugs". The report also pointed out that the EU requires Bayer to modify the drug instructions of these four related contraceptives and add the latest safety investigation results. Among the four Bayer contraceptives that were revealed to be "under investigation" this time, Yasmin is the only Bayer contraceptive introduced in mainland China and is a prescription drug. It was officially launched in 2009 and is manufactured by Bayer Healthcare Co., Ltd. Guangzhou Branch. Produced by the company and still on sale.
Public information shows that Yasmin (trade name) is a prescription drug in China, and drospirenone and ethinylestradiol tablets are its product name. As for whether a recall will be considered, the person in charge of Yasmin products said that the incident has not been confirmed yet and he cannot respond to this. "I can only say that there are no plans to recall at the moment." Bayer Yasmin product manager said , Yasmin, as the fourth generation oral contraceptive, has a very small chance of forming thrombosis, which is almost the same as the incidence rate of similar drugs.
Talking about the survey data on medication risks, the head of the Chinese market for the women’s health product group of Bayer Schering Pharmaceuticals Co., Ltd. said, “We have noticed the two reports cited by the FDA, and we believe that The conclusion is not very well-founded, and the experimental methods also have obvious flaws."
Bayer pointed out, "Bayer is actively cooperating with the EU's investigation and currently has no plans to recall. In the Chinese market, we have not received a request from the State Food and Drug Administration." Bayer ( The manager of Yasmin (Yasmin), one of the four products under investigation, from the Ministry of Medicine of China confirmed to the Daily Economic News: "We have received a request from the EU to modify the instructions, and the decision to modify it has basically been determined." This person It pointed out that the EU requested to modify the instructions for Bayer's oral contraceptives this time, mainly requiring it to indicate that "the possibility of adverse reactions such as venous thrombosis in the fourth generation oral contraceptives is basically the same as that of the third generation products, and higher than that of the second generation products." ".